Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | BRD4 | O60885 | 10/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607434 | 0.91 | OPRK1 (0.46) | OPRK1LMNAPDE3AROCK2BRD4 | |
| SCHEMBL605960 | 0.89 | OPRK1 (0.51) | OPRK1LMNAPDE3AROCK2PDE4D | |
| SCHEMBL3235884 | 0.89 | OPRK1 (0.48) | OPRK1LMNAPDE3AROCK2BRD4 | |
| SCHEMBL604600 | 0.89 | OPRK1 (0.43) | OPRK1LMNAPDE3ABRD4PDE4D | |
| SCHEMBL6125005 | 0.88 | OPRK1 (0.51) | OPRK1LMNAPDE3AROCK2BRD4 | |
| SCHEMBL605629 | 0.87 | BRD4 (0.42) | OPRK1LMNAPDE3ABRD4 | |
| SCHEMBL607303 | 0.87 | LMNA (0.48) | OPRK1LMNAPDE3AROCK2BRD4 | |
| SCHEMBL607649 | 0.87 | LMNA (0.48) | OPRK1LMNAPDE3AROCK2BRD4 | |
| SCHEMBL607569 | 0.86 | LMNA (0.46) | OPRK1LMNAPDE3AROCK2BRD4 | |
| SCHEMBL10193352 | 0.85 | LMNA (0.55) | OPRK1LMNAPDE3ABRD4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8461153-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2139331-B1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | UNIV MICHIGAN (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242109-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-14 | — | — | US | disclosed |
| US-8188072-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110195959-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-11 | — | — | US | disclosed |
| US-7851465-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2217576-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | The Regents of the University of Michigan (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061916-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | OPRK1 118/4885LMNA 2002/4885PDE3A 2780/4885 |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | OPRK1 313/4885LMNA 2006/4885PDE3A 875/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | OPRK1 118/4885LMNA 2002/4885PDE3A 2780/4885 |
| US-20110195959-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | OPRK1 313/4885LMNA 2006/4885PDE3A 875/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | OPRK1 118/4885LMNA 2002/4885PDE3A 2780/4885 |
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | OPRK1 313/4885LMNA 2006/4885PDE3A 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.